FDA has indicated that an Advisory Committee meeting is not required at this timeIn-person late-cycle review meeting ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

The FDA is assessing the need for “further regulatory action” on Sarepta's Duchenne muscular dystrophy gene therapy in the ...

Capricor Therapeutics updates on Deramiocel BLA for duchenne muscular dystrophy: San Diego Thursday, June 26, 2025, 15:30 Hrs [IST] Capricor Therapeutics, a biotechnology company ...

Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, unveiled positive results in its sevasemten programme for Becker and Duchenne muscular dystrophies. The company ...

"We just try to take it one day at a time and do the best we can and enjoy every day," said 16-year-old Brandon's mother, ...

Three conditions that likely won’t qualify under the Department for Work and Pensions' new ‘severe conditions criteria’ have ...

Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase ...

Muscular Dystrophy is a degenerative disease that is particularly common in young boys and men. Joey, known for his "Canuck ...

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...